Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists establish new blood test to better evaluate prostate cancer

01.10.2008
An international study led by researchers at The Institute of Cancer Research will pave the way for a test to be used to better tailor treatments and hopefully extend the survival of men with aggressive forms of metastatic prostate cancer.

The study, to be published tomorrow for Cancer Clinical Research ( available online Oct 1,) has found that this analysis of Circulating Tumour Cells (CTC) can be utilised to study the prognosis of prostate cancer and is an independent indicator for overall survival of the disease.

Lead researcher Dr Johann de Bono at The Institute of Cancer Research and The Royal Marsden Hospital says:

“CTC testing, used in conjunction with the existing prostate specific antigen (PSA) test, may allow doctors to more accurately evaluate the effect of treatment on a patient’s tumour.”

“These studies are a very promising development, allowing cancer cells to be detected using a simple blood test and may eventually allow us to tailor cancer treatments to maximise the benefit for patients. Hopefully this will lead to improving the survival of patients with metastatic prostate cancer.”

The PSA test has been widely adopted as the benchmark test for prostate cancer in the UK, but it is not always possible to identify a clear relationship between a raised PSA level and the status of the disease.

Circulating tumour cells (CTCs) are cancer cells that have broken away from an existing tumour and have entered into the bloodstream. The presence of these cells in the blood provides valuable insights into disease progression.

This study has shown that the monitoring and detection of CTCs can provide valuable information on the patient’s prognosis. Further studies are taking place to evaluate if the CTC test may be used to allow doctors to make treatment decisions more quickly and more reliably for the benefit of patients.

The test has already been incorporated into several prostate cancer drug trials that are taking place at The Institute and The Royal Marsden.

The test has been cleared by the FDA in the United States to determine the prognosis of patients with metastatic breast, colorectal or prostate cancer.

The study was in partnership with the New-York based Memorial Sloan-Kettering Institute and involved 231 patients undergoing chemotherapy treatment. Sixty-five clinical centres in Europe and the U.S. took part in the study.

The patients underwent monthly CTC monitoring to measure the level of circulating tumour cells in the blood. A count of more than 5 CTC per 7.5 ml of blood was seen as an indicator towards an “unfavourable” prognosis whereas a count of less than 5 CTC per 7.5ml was considered “favourable”. This was compared with the progression of the metastatic prostate cancer tumours.

Cathy Beveridge | alfa
Further information:
http://www.icr.ac.uk

Further reports about: CTC Cancer PSA cancer cells new blood test prostate cancer tumour cells

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>